Skip to main content

Zurzuvae for Postpartum Depression Comes With High Cost

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 9, 2023.

By Physician’s Briefing Staff HealthDay Reporter

WEDNESDAY, Nov. 8, 2023 -- A new drug to treat postpartum depression will cost nearly $16,000 for a 14-day course of treatment, a price tag that has doctors worried that some patients will not be able to afford the medication.

Zurzuvae (zuranolone) was first approved by the U.S. Food and Drug Administration back in August, and it carried the distinction of being the first postpartum depression (PPD) drug that can be taken as a pill.

Despite the drug's high cost, drugmaker Sage Therapeutics said Tuesday that the drug should hit the market by December and that it and partner Biogen are now talking with insurers about coverage of the medication. The companies' goal is "to enable broad and equitable access for women with PPD who are prescribed this drug," Sage Chief Executive Officer Barry Greene said in a company news release. The hope is for patients to be able to get the medicine, "where possible, with little to no copay regardless of financial means." He added that the two companies will also help cover costs or provide the drug free to certain patients.

Mental health experts have welcomed the drug's approval, not just because it presents a new way to treat postpartum depression, but also because it "appears to be fast-acting," Catherine Monk, M.D., chief of the Division of Women's Mental Health in the Department of Obstetrics and Gynecology at the Columbia University Vagelos College of Physicians and Surgeons in New York City, told CNN.

In one company trial, Zurzuvae improved depressive symptoms in as little as three days. Prior to the drug's approval, options to treat postpartum depression orally included selective serotonin reuptake inhibitors (SSRIs), but those antidepressants "take weeks to kick in and must continue being taken on a daily basis for at least six to 12 months," Katrina Furey, M.D., a psychiatrist specializing in women's mental health and reproductive psychiatry and a clinical instructor at Yale University in New Haven, Connecticut, told CNN.

"It remains to be seen how much insurance companies will cover it or if they will require women to 'fail' treatment with less expensive SSRIs before paying for this new treatment," Furey said. "I hope that is not the case and that its price will not be a barrier to accessing this treatment."

CNN Article

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted November 2023

Read this next

Postpartum Low-Dose Esketamine Aids Moms With Prenatal Depression

MONDAY, April 15, 2024 -- A single low dose of esketamine after childbirth reduces depressive episodes at 42 days postpartum among mothers with prenatal depression, according to a...

ED Use Up for Infants of Mothers With Depressive Symptoms

TUESDAY, April 2, 2024 -- Infants with mothers with depressive symptoms have higher overall and nonemergent emergency department use, according to a study published in the April...

Premenstrual Disorder Linked to Perinatal Depression

TUESDAY, April 2, 2024 -- There is a bidirectional association between premenstrual disorders (PMDs) and perinatal depression (PND), according to a study published online March 28...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.